EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anaplastic large cell lymphoma in children and adolescents

Eric J Lowe, Wilhelm Woessmann iD

British Journal of Haematology · 2025-08 · 207 (2) · 336-349

DOI: 10.1111/bjh.20154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 12.05.2025. Verfasst von Eric J Lowe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Eastern Virginia Medical School at Old Dominion University, Norfolk, Virginia, USA. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic lymphoma kinase (ALK)‐positive anaplastic large‐cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30‐positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23. The pathogenesis of ALK‐positive ALCL is based on signalling from the constitutive active ALK kinase. The clinical characteristics, therapy regimens and outcome data were reported in the 1990s and 2000s. Different chemotherapy regimens led to astonishingly similar long‐term event‐free survival rates of 70%, independent of the drugs, doses and duration of therapy. Additionally, patients with relapsed ALCL are treated successfully with very different re‐induction and consolidation approaches leading to an overall survival approaching 95%. In the 2010s, minimal disseminated and residual disease, histological subtype and antibody titres against ALK were reported as significant independent prognostic factors. Over the last 15 years, targeted therapies (brentuximab vedotin, ALK inhibitors) have demonstrated high efficacy with low toxicity. The future of ALK‐positive ALCL is to define the role of targeted therapies by developing a ‘chemotherapy‐free’ approach for patients with standard‐risk ALCL and an integrated approach to cure patients with high‐risk ALCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large-Cell, AnaplasticHumansChildAdolescentAnaplastic Lymphoma KinasePrognosisMolecular Targeted TherapyBrentuximab VedotinTyrosine Kinase InhibitorsImmune Checkpoint InhibitorsRecurrence

Stichwörter der Autor:innen

anaplastic large‐cell lymphomaanaplastic lymphoma kinasechildrendiagnosistherapy

Substanzen

ALK protein, humanAnaplastic Lymphoma KinaseBrentuximab VedotinTyrosine Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pediatrics, Eastern Virginia Medical School at Old Dominion University, Norfolk, Virginia, USA.
  • Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Wilhelm Woessmann

Zitieren

APA

Lowe, E. J., & Woessmann, W. (2025). Anaplastic large cell lymphoma in children and adolescents. British Journal of Haematology, 207(2), 336-349. https://doi.org/10.1111/bjh.20154

Vancouver

Lowe EJ, Woessmann W. Anaplastic large cell lymphoma in children and adolescents. British Journal of Haematology. 2025;207(2):336-349. doi:10.1111/bjh.20154

BibTeX
@article{Lowe2025,
  author = {Lowe, Eric J and Woessmann, Wilhelm},
  title = {Anaplastic large cell lymphoma in children and adolescents},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {2},
  pages = {336--349},
  doi = {10.1111/bjh.20154}
}
Kostenlos starten →